Literature DB >> 16187338

In vitro galactosylation of human IgG at 1 kg scale using recombinant galactosyltransferase.

Dale Warnock1, Xiaomei Bai, Katie Autote, Johnny Gonzales, Kyle Kinealy, Boxu Yan, Jun Qian, Tom Stevenson, David Zopf, Robert J Bayer.   

Abstract

The Fc effector functions of immunoglobulin G (IgG) antibodies are in part determined by structural features of carbohydrates linked to each of the paired gamma heavy chains in the antibody constant domain (C(H)2). One glycoform that has been shown to be advantageous is G2, where both arms of complex bi-antennary N-glycans terminate in galactose. In vitro treatment with glycosyltransferases can remodel heterogeneous IgG glycoforms, enabling preparation of IgG molecules with homogeneous glycan chains. Here we describe optimization of conditions for use of a soluble recombinant galactosyltransferase in vitro to remodel glycans of human serum IgG, and we demonstrate a scaled-up reaction in which >98% of neutral glycans attached to 1 kg IgG are converted to the G2 glycoform. Removal of glycosylation reagents from the product is achieved in one step by affinity chromatography on immobilized Protein A. Copyright 2005 Wiley Periodicals, Inc

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16187338     DOI: 10.1002/bit.20658

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  15 in total

1.  The impact of glycosylation on monoclonal antibody conformation and stability.

Authors:  Kai Zheng; Christopher Bantog; Robert Bayer
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

2.  Modifications of therapeutic proteins: challenges and prospects.

Authors:  Nigel Jenkins
Journal:  Cytotechnology       Date:  2007-05-25       Impact factor: 2.058

3.  Post-translational modifications differentially affect IgG1 conformation and receptor binding.

Authors:  Damian Houde; Yucai Peng; Steven A Berkowitz; John R Engen
Journal:  Mol Cell Proteomics       Date:  2010-01-26       Impact factor: 5.911

4.  Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab.

Authors:  Carola W N Damen; Weibin Chen; Asish B Chakraborty; Mike van Oosterhout; Jeffrey R Mazzeo; John C Gebler; Jan H M Schellens; Hilde Rosing; Jos H Beijnen
Journal:  J Am Soc Mass Spectrom       Date:  2009-08-07       Impact factor: 3.109

5.  Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc.

Authors:  Robert M Anthony; Falk Nimmerjahn; David J Ashline; Vernon N Reinhold; James C Paulson; Jeffrey V Ravetch
Journal:  Science       Date:  2008-04-18       Impact factor: 47.728

6.  Impact of N-glycosylation on Fcγ receptor / IgG interactions: unravelling differences with an enhanced surface plasmon resonance biosensor assay based on coiled-coil interactions.

Authors:  Florian Cambay; Olivier Henry; Yves Durocher; Gregory De Crescenzo
Journal:  MAbs       Date:  2019-03-05       Impact factor: 5.857

Review 7.  Emerging methods for the production of homogeneous human glycoproteins.

Authors:  Jamie R Rich; Stephen G Withers
Journal:  Nat Chem Biol       Date:  2009-04       Impact factor: 15.040

Review 8.  Chemoenzymatic Methods for the Synthesis of Glycoproteins.

Authors:  Chao Li; Lai-Xi Wang
Journal:  Chem Rev       Date:  2018-08-24       Impact factor: 60.622

9.  Enzyme-mediated methodology for the site-specific radiolabeling of antibodies based on catalyst-free click chemistry.

Authors:  Brian M Zeglis; Charles B Davis; Robert Aggeler; Hee Chol Kang; Aimei Chen; Brian J Agnew; Jason S Lewis
Journal:  Bioconjug Chem       Date:  2013-05-30       Impact factor: 4.774

Review 10.  Site-specific linking of biomolecules via glycan residues using glycosyltransferases.

Authors:  Pradman K Qasba; Elizabeth Boeggeman; Boopathy Ramakrishnan
Journal:  Biotechnol Prog       Date:  2008-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.